ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
You may also be interested in...
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
Arrowhead’s drug has failed to match performance, but its RNAi platform has other promising candidates.